{"id":64591,"date":"2026-05-14T13:10:28","date_gmt":"2026-05-14T11:10:28","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/05\/14\/combined-cyclosporine-a-and-urolithin-a-therapy-ameliorates-murine-lupus-nephritis\/"},"modified":"2026-05-14T13:10:28","modified_gmt":"2026-05-14T11:10:28","slug":"combined-cyclosporine-a-and-urolithin-a-therapy-ameliorates-murine-lupus-nephritis","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/05\/14\/combined-cyclosporine-a-and-urolithin-a-therapy-ameliorates-murine-lupus-nephritis\/","title":{"rendered":"Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Apr 15;215(4):vkag087. doi: 10.1093\/jimmun\/vkag087.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Monotherapies for lupus nephritis (LN) often fail to fully control the disease&#8217;s hallmark, renal inflammation and immune complex deposition. This study investigates a novel combination therapeutic strategy using urolithin A (UA), a multifaceted anti-inflammatory and antioxidant agent, with cyclosporine A (CsA), an established immunosuppressant. The combination therapy&#8217;s superior efficacy is evidenced by a robust reduction in immunoglobulin G (IgG) anti-dsDNA levels, with markedly improved renal function. The treatment also effectively mitigated immune complex deposition and multiple inflammatory chemokines, including I309, IL-16, and MIP-3. This alleviated kidney damage and suppressed lymphocyte infiltration. We found that CsA alone was ineffective across the analyzed markers, while UA alone produced only a modest effect, highlighting the complementary action of their combination. These findings underscore the potent anti-inflammatory and antioxidant properties of UA and suggest that combining it with CsA offers a more robust strategy for controlling inflammation and preserving renal integrity in LN. Given the FDA-approved status of CsA and UA&#8217;s &#8220;generally recognized as safe&#8221; (GRAS) classification, this combination therapy presents a promising and practical clinical pathway for the treatment of lupus nephritis.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42130005\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260514071028&amp;v=2.20.0\">42130005<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag087\">10.1093\/jimmun\/vkag087<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Apr 15;215(4):vkag087. doi: 10.1093\/jimmun\/vkag087. ABSTRACT Monotherapies for lupus nephritis (LN) often fail to fully control the disease&#8217;s hallmark, renal inflammation and immune complex deposition. This study investigates a novel combination therapeutic strategy using urolithin A (UA), a multifaceted anti-inflammatory and antioxidant agent, with cyclosporine A (CsA), an established immunosuppressant. The combination therapy&#8217;s &#8230; <a title=\"Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/05\/14\/combined-cyclosporine-a-and-urolithin-a-therapy-ameliorates-murine-lupus-nephritis\/\" aria-label=\"Read more about Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-64591","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/64591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=64591"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/64591\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=64591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=64591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=64591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}